For more and to view the abstract, visit the AACR Annual Meeting ... negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not ...

Tvardi Therapeutics, Inc. ("Tvardi") , a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, ...

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT ...

Ontada to present 14 data presentations at ISPOR 2025 including a podium presentation on distress thermometer screening in US oncology setting ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

These presentations further reinforce our technology leadership and our highly differentiated ADC candidates.” The abstracts are currently available on AACR’s website and the poster ...

May 13-15: Clinical Trial Supply Forum 2025. Kimi Oanh Le, Head of Clinical Trial Supply at Immunic, will discuss the clinical trial supply chain challenges working across the Middle East and North ...

There are no format restrictions ... when you are writing yours. Abstracts do not need to include references, parenthetical citations, footnotes, or a works cited page. Please proofread and rehearse ...

Contributions on the topics listed in the Conference Announcement under Section C are welcome as oral or poster presentations ... format of the contributed papers and for the preparation of posters ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...